Momentum is building for Dogwood Therapeutics (DWTX) as its Phase 2b program moves toward a key interim analysis. With its lead candidate Halneuron advancing through a Phase 2b trial for chemotherapy-induced neuropathic pain (CINP), the next few quarters will be critical in shaping Dogwood's future.
HALT-CINP Trial Progress
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com